Anakmeteeprugsa Suthawan, Gonzalez-Fiol Antonio, Garay Angelique, Lin Hung-Mo, He Zili, Alian Aymen
Department of Anesthesiology, Yale University School of Medicine, PO Box 208051, 333 Cedar Street, New Haven, CT, 06520, USA.
Faculty of Medicine Siriraj Hospital, Department of Anesthesiology, Golden Jubilee Medical Center , Mahidol University, Nakhon Pathom, Thailand.
BMC Pregnancy Childbirth. 2025 Aug 8;25(1):826. doi: 10.1186/s12884-025-07927-z.
Hypofibrinogenemia is associated with progression from moderate to severe postpartum hemorrhage (PPH). Early recognition and replacement of fibrinogen are emphasized during the management of PPH. The Quantra QPlus System, a novel point-of-care viscoelastic testing (POCVT) device, has been designed to provide rapid assessment of hemostasis. We aimed to evaluate the correlation between Quantra parameters and standard laboratory coagulation tests, and to establish baseline Quantra values in healthy term pregnant women.
Healthy pregnant women in labor or scheduled for elective cesarean delivery (CD) were enrolled in our prospective observational study. Blood samples for Quantra and standard laboratory coagulation tests were taken simultaneously. Quantra values, standard laboratory coagulation test, time of blood collected, and time to the result were recorded. We compared the baseline values between CD and labor group using a t-test, and the correlation between Quantra and standard laboratory coagulation test was calculated using partial Pearson correlation.
170 healthy pregnant women were included; 126 cases were in the CD group, and 44 patients were in the labor group. We found a strong correlation between Quantra Fibrinogen contribution to Clot Stiffness (FCS) and fibrinogen level (r = 0.67). The median [interquartile range] time of fibrinogen results by Quantra was 36 [28, 48] minutes faster than the standard laboratory coagulation tests. Baseline ranges for Quantra values, which were not significantly different between the two groups, demonstrated hyperfibrinogenemia during pregnancy.
Quantra is a novel POCVT device that rapidly provides coagulation status in pregnant women. The strong correlation between FCS and fibrinogen level can be helpful for early recognition of hypofibrinogenemia for the management of PPH.
低纤维蛋白原血症与产后出血(PPH)从中度进展至重度相关。PPH管理过程中强调对纤维蛋白原的早期识别和补充。Quantra QPlus系统是一种新型的即时床旁粘弹性检测(POCVT)设备,旨在快速评估止血情况。我们旨在评估Quantra参数与标准实验室凝血试验之间的相关性,并确定健康足月孕妇的Quantra基线值。
纳入正在分娩或计划择期剖宫产(CD)的健康孕妇进行前瞻性观察研究。同时采集用于Quantra检测和标准实验室凝血试验的血样。记录Quantra值、标准实验室凝血试验结果、采血时间和出结果时间。我们使用t检验比较CD组和分娩组之间的基线值,并使用偏Pearson相关性计算Quantra与标准实验室凝血试验之间的相关性。
共纳入170例健康孕妇;CD组126例,分娩组44例。我们发现Quantra纤维蛋白原对血凝块硬度的贡献(FCS)与纤维蛋白原水平之间存在强相关性(r = 0.67)。Quantra检测纤维蛋白原结果的中位[四分位间距]时间比标准实验室凝血试验快36[28, 48]分钟。两组之间Quantra值的基线范围无显著差异,显示孕期存在高纤维蛋白原血症。
Quantra是一种新型的POCVT设备,可快速提供孕妇的凝血状态。FCS与纤维蛋白原水平之间的强相关性有助于早期识别低纤维蛋白原血症以管理PPH。